Mucocutaneous manifestations of disseminated histoplasmosis in patients with acquired immunodeficiency syndrome: particular aspects in a Latin-American population.
BACKGROUND
Mucocutaneous lesions in human immunodeficiency virus (HIV)-infected patients with disseminated histoplasmosis have a wide spectrum of clinical manifestations, making its diagnosis difficult. Studies have been restricted to case reports and series with small numbers of patients not specifically focusing on the dermatological aspects of histoplasmosis.


OBJECTIVE
To describe the characteristics of mucocutaneous lesions of disseminated histoplasmosis in HIV-infected patients.


METHODS
A retrospective and prospective study was conducted on 36 HIV-infected patients with mucocutaneous histoplasmosis in a tertiary-care hospital in Brazil.


RESULTS
Mucocutaneous histoplasmosis was diagnosed by histopathology in 33 of the 36 patients (91%) and/or culture in 23 (64%). Their CD4+ cell counts ranged from 2 to 103 cells/mm(3). The average number of different morphological types of lesions was three per patient. Despite the variability of the lesions, papules (50%), crusted papules (64%) and oral mucosal erosions and/or ulcers (58%) were the most frequent dermatological lesions. A diffuse pattern of distribution of the skin lesions was found in 58% of the cases. There was significant association between the CD4+ cell counts and the morphological variability of lesions per patient. Variation in the lesions seemed to be associated with higher CD4+ cell counts.


CONCLUSIONS
Doctors caring for HIV-infected patients should be aware of the wide spectrum of dermatological lesions observed in disseminated histoplasmosis and the importance of detecting and isolating the fungus in mucocutaneous tissues.
Cunha
V S
VS
Department of Dermatology, Porto Alegre Clinical Hospital, Federal University of Rio Grande do Sul, Brazil. vscunha@yahoo.com
Zampese
M S
MS
Aquino
V R
VR
Cestari
T F
TF
Goldani
L Z
LZ
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000382:microbiology; D000328:Adult; D000935:Antifungal Agents / Q000627:therapeutic use*; D001938:Brazil / Q000453:epidemiology; D003881:Dermatomycoses / Q000188:drug therapy* / Q000382:microbiology; D005260:Female; D006660:Histoplasmosis / Q000188:drug therapy*; D006801:Humans; D008297:Male; D011446:Prospective Studies; D012189:Retrospective Studies
D000935:Antifungal Agents